J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
More News related to SNY
- First Commercial Order for Changda International's Thiophene from French Drug Giant
- Sanofi-aventis (SNY) Signs Licensing Agreement with Intelliject
- Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
- Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
More News related to Downgrades
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
- EQT Corp.'s (EQT) Board Approves Capital Budget for 2010
- Morgan Stanley (MS) may restructure its real estate fund -WSJ
J.P. Morgan downgrades Sanofi-Aventis (NYSE: SNY) from Overweight to Neutral.
To see more analyst ratings on SNY Click Here.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Related Categories
DowngradesStocks Mentioned
+0.43Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
